ITGAM and neoplasm: We show that rosiglitazone suppressed PDV tumor cell proliferation in immune competent, but not immunodeficient mice after 59 days of growth (when CD11b+Gr-1+ cells were the predominant myeloid cell type in the tumor microenvironment).